Abstract
Stroke is the fifth leading cause of death in the United States with a huge burden on health care. Acute ischemic stroke (AIS) accounts for 87% of all stroke. The use of thrombolytic agents in AIS treatment is well known since 1950 but no FDA approval until 1996, due to lack of strong evidence showing benefits outweigh the risk of intracranial hemorrhage. The NINDS trial led to the approval of intravenous tissue plasminogen activator treatment (IV recombinant tPA) within 3 h of stroke. Due to this limitation of 3–4.5 h. window, evolution began in the development of effective endovascular therapy (EVT). Multiple trials were unsuccessful in establishing the strong evidence for effectiveness of EVT. In 2015, MR CLEAN trial made progress and showed improved outcomes with EVT in AIS patients with large vessel occlusion (LVO), with 6-h window period. In 2018, two major trials—DAWN and DEFUSE 3—along with few other trials had shown improved outcomes with EVT and stretched window period from 6 to 24 h. AHA Stroke Council is constantly working to provide focused guidelines and recommendations in AIS management since 2013. SVIN had started the initiative “Mission Thrombectomy-2020” to increase global EVT utilization rate 202,000 procedures by 2020. Physicians are using safer and easier approach like brachial and radial approach for EVT. TeleNeurology and artificial intelligence also played a significant role in increasing the availability of IV recombinant tPA in AIS treatment in remote hospitals and also in screening, triaging and identifying LVO patients for EVT. In this review article, we aim to describe the history of stroke management along with the new technological advancements in AIS treatment.
This is a preview of subscription content,
to check access.References
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, Ferranti SDd, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P (2017) Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135(10):e146–e603. https://doi.org/10.1161/CIR.0000000000000485
Snow SJ (2016) Stroke and t-PA–triggering new paradigms of care. N Engl J Med 374(9):809–811. https://doi.org/10.1056/NEJMp1514696
Fisher M, Schaebitz W (2000) An overview of acute stroke therapy: past, present, and future. Arch Intern Med 160(21):3196–3206. https://doi.org/10.1001/archinte.160.21.3196
Tissue plasminogen activator for acute ischemic stroke (1995) N Engl J Med 333 (24):1581–1587. https://doi.org/10.1056/nejm199512143332401
Chugh C (2019) Acute ischemic stroke: management approach. Indian J Crit Care Med 23(Suppl 2):S140–S146. https://doi.org/10.5005/jp-journals-10071-23192
Goldstein LB (2014) Modern medical management of acute ischemic stroke. Methodist Debakey Cardiovasc J 10(2):99–104. https://doi.org/10.14797/mdcj-10-2-99
Damani R (2018) A brief history of acute stroke care. Aging (Albany NY) 10(8):1797–1798. https://doi.org/10.18632/aging.101542
Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282(21):2003–2011. https://doi.org/10.1001/jama.282.21.2003
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millan M, Davis SM, Roy D, Thornton J, Roman LS, Ribo M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387(10029):1723–1731. https://doi.org/10.1016/s0140-6736(16)00163-x
Gandhi CD, Al Mufti F, Singh IP, Abruzzo T, Albani B, Ansari SA, Arthur AS, Bain M, Baxter BW, Bulsara KR, Caplan JM, Chen M, Dabus G, Frei D, Hetts SW, Hussain MS, Jayaraman MV, Kayan Y, Klucznik RP, Lee SK, Mack WJ, Leslie-Mazwi T, McTaggart RA, Meyers PM, Mokin M, Patsalides AT, Prestigiacomo CJ, Pride GL Jr, Starke RM, Sunenshine PJ, Fraser JF (2018) Neuroendovascular management of emergent large vessel occlusion: update on the technical aspects and standards of practice by the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery. J Neurointerv Surg 10(3):315–320. https://doi.org/10.1136/neurintsurg-2017-013554
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG (2018) Thrombectomy 6–24 h after stroke with a mismatch between deficit and infarct. N Engl J Med 378(1):11–21. https://doi.org/10.1056/NEJMoa1706442
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG (2018) Thrombectomy for stroke at 6–16 h with selection by perfusion imaging. N Engl J Med 378(8):708–718. https://doi.org/10.1056/NEJMoa1713973
Ragoschke-Schumm A, Walter S (2018) DAWN and DEFUSE-3 trials: is time still important? (Die DAWN- und DEFUSE-3-Studie: ist Zeit immer noch wichtig?). Radiologe 58(Suppl 1):20–23. https://doi.org/10.1007/s00117-018-0406-4
Nannoni S, Strambo D, Sirimarco G, Amiguet M, Vanacker P, Eskandari A, Saliou G, Wintermark M, Dunet V, Michel P (2019) Eligibility for late endovascular treatment using DAWN, DEFUSE-3, and more liberal selection criteria in a stroke center. J Neurointerv Surg. https://doi.org/10.1136/neurintsurg-2019-015382
Almekhlafi MA, Kunz WG, McTaggart RA, Jayaraman MV, Najm M, Ahn SH, Fainardi E, Rubiera M, Khaw AV, Zini A, Hill MD, Demchuk AM, Goyal M, Menon BK (2020) Imaging triage of patients with late-window (6–24 h) acute ischemic stroke: a comparative study using multiphase CT angiography versus CT perfusion. AJNR Am J Neuroradiol 41(1):129–133. https://doi.org/10.3174/ajnr.A6327
Hill M, Glenn BA, Reese BJ, Morrow B (2018) Recommendations for endovascular care of stroke patients. Interv Neurol 7(1–2):65–90. https://doi.org/10.1159/000481541
Chen SH, Snelling BM, Sur S, Shah SS, McCarthy DJ, Luther E, Yavagal DR, Peterson EC, Starke RM (2019) Transradial versus transfemoral access for anterior circulation mechanical thrombectomy: comparison of technical and clinical outcomes. J Neurointerv Surg 11(9):874–878. https://doi.org/10.1136/neurintsurg-2018-014485
Lunagariya A, Patel A, Dalal S, Jani V, Nagaraja N, Huisa B, Hemmen T, Ovbiagele B, Patel U (2018) Abstract TMP84: substantial rise in tPA utilization for acute ischemic stroke in the United States corresponds with significant improvement in outcomes. Stroke 49(Suppl_1):ATMP84. https://doi.org/10.1161/str.49.suppl_1.TMP84
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL (2019) Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50(12):e344–e418. https://doi.org/10.1161/STR.0000000000000211
Ren Z, Mokin M, Bauer CT, Miao Z, Burgin WS, Wang Y (2019) Indications for mechanical thrombectomy—too wide or too narrow? World Neurosurg 127:492–499. https://doi.org/10.1016/j.wneu.2019.04.116
Shams T, Zaidat O, Yavagal D, Xavier A, Jovin T, Janardhan V (2016) Society of Vascular and interventional neurology (SVIN) stroke interventional laboratory consensus (SILC) criteria: A 7M management approach to developing a stroke interventional laboratory in the era of stroke thrombectomy for large vessel occlusions. Interv Neurol 5(1–2):1–28. https://doi.org/10.1159/000443617
Prasad K, Sharma A, Garg A, Mohanty S, Bhatnagar S, Johri S, Singh KK, Nair V, Sarkar RS, Gorthi SP, Hassan KM, Prabhakar S, Marwaha N, Khandelwal N, Misra UK, Kalita J, Nityanand S (2014) Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial. Stroke 45(12):3618–3624. https://doi.org/10.1161/strokeaha.114.007028
Savitz SI, Yavagal D, Rappard G, Likosky W, Rutledge N, Graffagnino C, Alderazi Y, Elder JA, Chen PR, Budzik RF, Tarrel R, Huang DY, Hinson JM (2019) A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow–derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVER-Stroke). Circulation 139(2):192–205. https://doi.org/10.1161/circulationaha.117.030659
Vu Q, Xie K, Eckert M, Zhao W, Cramer SC (2014) Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology 82(14):1277–1286. https://doi.org/10.1212/WNL.0000000000000278
Kenmuir CL, Wechsler LR (2017) Update on cell therapy for stroke. Stroke Vasc Neurol 2(2):59. https://doi.org/10.1136/svn-2017-000070
Patel UK, Malik P, DeMasi M, Lunagariya A, Jani VB (2019) Multidisciplinary approach and outcomes of tele-neurology: a review. Cureus 11(4):e4410. https://doi.org/10.7759/cureus.4410
Mazighi M, Meseguer E, Labreuche J, Miroux P, Le Gall C, Roy P, Tubach F, Amarenco P (2017) TRUST-tPA trial: telemedicine for remote collaboration with urgentists for stroke-tPA treatment. J Telemed Telecare 23(1):174–180. https://doi.org/10.1177/1357633x15615762
Amorim E, Shih MM, Koehler SA, Massaro LL, Zaidi SF, Jumaa MA, Reddy VK, Hammer MD, Jovin TG, Wechsler LR (2013) Impact of telemedicine implementation in thrombolytic use for acute ischemic stroke: the University of Pittsburgh Medical Center telestroke network experience. J Stroke Cerebrovasc Dis 22(4):527–531. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.02.004
Barlinn J, Gerber J, Barlinn K, Pallesen LP, Siepmann T, Zerna C, Wojciechowski C, Puetz V, von Kummer R, Reichmann H, Linn J, Bodechtel U (2017) Acute endovascular treatment delivery to ischemic stroke patients transferred within a telestroke network: a retrospective observational study. Int J Stroke 12(5):502–509. https://doi.org/10.1177/1747493016681018
Kunz A, Ebinger M, Geisler F, Rozanski M, Waldschmidt C, Weber JE, Wendt M, Winter B, Zieschang K, Fiebach JB, Villringer K, Erdur H, Scheitz JF, Tutuncu S, Bollweg K, Grittner U, Kaczmarek S, Endres M, Nolte CH, Audebert HJ (2016) Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study. Lancet Neurol 15(10):1035–1043. https://doi.org/10.1016/s1474-4422(16)30129-6
Patel UK, Anwar A, Saleem S, Malik P, Rasul B, Patel K, Yao R, Seshadri A, Yousufuddin M, Arumaithurai K (2019) Artificial intelligence as an emerging technology in the current care of neurological disorders. J Neurol. https://doi.org/10.1007/s00415-019-09518-3
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne M-H, Hennerici M (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13):1017–1025. https://doi.org/10.1001/jama.1995.03530130023023
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). The Lancet 352(9136):1245–1251. https://doi.org/10.1016/S0140-6736(98)08020-9
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, Investigators ftAS, (1999) Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3–5 h after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA 282(21):2019–2026. https://doi.org/10.1001/jama.282.21.2019
Albers GW, Clark WM, Madden KP, Hamilton SA (2002) ATLANTIS trial: results for patients treated within 3 h of stroke onset alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke 33(2):493–495. https://doi.org/10.1161/hs0202.102599
Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T (2007) Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 38(10):2633–2639. https://doi.org/10.1161/strokeaha.107.488551
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3–4.5 h after acute ischemic stroke. N Engl J Med 359(13):1317–1329. https://doi.org/10.1056/NEJMoa0804656
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Ang T, Miteff F, Levi CR, Rodrigues E, Zhao H, Salvaris P, Garcia-Esperon C, Bailey P, Rice H, de Villiers L, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Wong AA, Muller C, Coulthard A, Mitchell K, Clouston J, Mahady K, Field D, Ma H, Phan TG, Chong W, Chandra RV, Slater LA, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM (2018) Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 378(17):1573–1582. https://doi.org/10.1056/NEJMoa1716405
Ringleb P, Bendszus M, Bluhmki E, Donnan G, Eschenfelder C, Fatar M, Kessler C, Molina C, Leys D, Muddegowda G, Poli S, Schellinger P, Schwab S, Serena J, Toni D, Wahlgren N, Hacke W (2019) Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. Int J Stroke 14(5):483–490. https://doi.org/10.1177/1747493019840938
Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Zhao H, Alemseged F, Ng F, Bailey P, Rice H, de Villiers L, Dewey HM, Choi PMC, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Kraemer T, Krause M, Cordato D, Field D, Ma H, O'Brien B, Clissold B, Miteff F, Clissold A, Cloud GC, Bolitho LE, Bonavia L, Bhattacharya A, Wright A, Mamun A, O'Rourke F, Worthington J, Wong AA, Levi CR, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM (2020) Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2020.1511
Zoppo GJd, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M (1998) PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 29(1):4–11. https://doi.org/10.1161/01.STR.29.1.4
Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T (1999) Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30(12):2598–2605. https://doi.org/10.1161/01.str.30.12.2598
Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman IE, Higashida RT, Budzik RF, Marks MP (2005) Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36(7):1432–1438. https://doi.org/10.1161/01.STR.0000171066.25248.1d
The Interventional Management of Stroke (IMS) II Study (2007) Stroke 38 (7):2127–2135. https://doi.org/10.1161/STROKEAHA.107.483131
Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP, Frei D, Grobelny T, Hellinger F, Huddle D, Kidwell C, Koroshetz W, Marks M, Nesbit G, Silverman IE (2008) Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 39(4):1205–1212. https://doi.org/10.1161/strokeaha.107.497115
The Penumbra Pivotal Stroke Trial (2009) Stroke 40 (8):2761–2768. https://doi.org/10.1161/Strokeaha.108.544957
Castaño C, Dorado L, Guerrero C, Millán M, Gomis M, Ossa NPdl, Castellanos M, García MR, Domenech S, Dávalos A, (2010) Mechanical thrombectomy with the solitaire AB device in large artery occlusions of the anterior circulation. Stroke 41(8):1836–1840. https://doi.org/10.1161/Strokeaha.110.584904
Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL (2013) A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368(10):914–923. https://doi.org/10.1056/NEJMoa1212793
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, Dowlatshahi D, Frei DF, Kamal NR, Montanera WJ, Poppe AY, Ryckborst KJ, Silver FL, Shuaib A, Tampieri D, Williams D, Bang OY, Baxter BW, Burns PA, Choe H, Heo J-H, Holmstedt CA, Jankowitz B, Kelly M, Linares G, Mandzia JL, Shankar J, Sohn S-I, Swartz RH, Barber PA, Coutts SB, Smith EE, Morrish WF, Weill A, Subramaniam S, Mitha AP, Wong JH, Lowerison MW, Sajobi TT, Hill MD (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372(11):1019–1030. https://doi.org/10.1056/NEJMoa1414905
Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Baxter BW, Devlin TG, Lopes DK, Reddy VK, du Mesnil de Rochemont R, Singer OC, Jahan R, (2015) Stent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke. N Engl J Med 372(24):2285–2295. https://doi.org/10.1056/NEJMoa1415061
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot J-M, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG (2017) Thrombectomy 6–24 h after stroke with a mismatch between deficit and infarct. N Engl J Med 378(1):11–21. https://doi.org/10.1056/NEJMoa1706442
Funding
No targeted funding reported.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Malik, P., Anwar, A., Patel, R. et al. Expansion of the dimensions in the current management of acute ischemic stroke. J Neurol 268, 3185–3202 (2021). https://doi.org/10.1007/s00415-020-09873-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-09873-6